DK1352896T3 - Adamantanderivater til behandling af inflammations-, immun- og hjertekarsygdomme - Google Patents

Adamantanderivater til behandling af inflammations-, immun- og hjertekarsygdomme

Info

Publication number
DK1352896T3
DK1352896T3 DK03013990T DK03013990T DK1352896T3 DK 1352896 T3 DK1352896 T3 DK 1352896T3 DK 03013990 T DK03013990 T DK 03013990T DK 03013990 T DK03013990 T DK 03013990T DK 1352896 T3 DK1352896 T3 DK 1352896T3
Authority
DK
Denmark
Prior art keywords
immune
inflammatory
treatment
cardiovascular diseases
adamantan
Prior art date
Application number
DK03013990T
Other languages
English (en)
Inventor
Mark Furber
Michael Mortimore
Lilian Alcaraz
Timothy Luker
Philip Thorne
Paul Willis
Austen Pimm
Moya Caffrey
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9904651A external-priority patent/SE9904651D0/xx
Priority claimed from GB0015744A external-priority patent/GB0015744D0/en
Priority claimed from GB0017942A external-priority patent/GB0017942D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1352896T3 publication Critical patent/DK1352896T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes
DK03013990T 1999-12-17 2000-12-12 Adamantanderivater til behandling af inflammations-, immun- og hjertekarsygdomme DK1352896T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9904651A SE9904651D0 (sv) 1999-12-17 1999-12-17 Novel compounds
GB0015744A GB0015744D0 (en) 2000-06-27 2000-06-27 Novel compounds
GB0017942A GB0017942D0 (en) 2000-07-22 2000-07-22 Novel compounds
PCT/SE2000/002505 WO2001044170A1 (en) 1999-12-17 2000-12-12 Adamantane derivatives

Publications (1)

Publication Number Publication Date
DK1352896T3 true DK1352896T3 (da) 2008-01-28

Family

ID=27255782

Family Applications (4)

Application Number Title Priority Date Filing Date
DK03013990T DK1352896T3 (da) 1999-12-17 2000-12-12 Adamantanderivater til behandling af inflammations-, immun- og hjertekarsygdomme
DK03013989T DK1352895T3 (da) 1999-12-17 2000-12-12 Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme
DK00986155T DK1242364T3 (da) 1999-12-17 2000-12-12 Adamantanderivater
DK03013991T DK1352897T3 (da) 1999-12-17 2000-12-12 Adamantanderivater til behandlingen af inflammatoriske sygdomme, immunsygdomme og cardiovaskulære sygdomme

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK03013989T DK1352895T3 (da) 1999-12-17 2000-12-12 Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme
DK00986155T DK1242364T3 (da) 1999-12-17 2000-12-12 Adamantanderivater
DK03013991T DK1352897T3 (da) 1999-12-17 2000-12-12 Adamantanderivater til behandlingen af inflammatoriske sygdomme, immunsygdomme og cardiovaskulære sygdomme

Country Status (32)

Country Link
US (5) US6881754B2 (da)
EP (5) EP1862451A1 (da)
JP (2) JP3710418B2 (da)
KR (2) KR20070012883A (da)
CN (1) CN1312120C (da)
AR (1) AR035325A1 (da)
AT (4) ATE261933T1 (da)
AU (2) AU780506B2 (da)
BR (1) BRPI0016395B8 (da)
CA (1) CA2393352C (da)
CO (1) CO5251381A1 (da)
CY (3) CY1106357T1 (da)
CZ (1) CZ20022093A3 (da)
DE (4) DE60036968T2 (da)
DK (4) DK1352896T3 (da)
EE (1) EE05134B1 (da)
ES (4) ES2294219T3 (da)
HK (2) HK1057035A1 (da)
HU (1) HUP0300616A3 (da)
IL (2) IL150124A0 (da)
IS (1) IS2246B (da)
MX (1) MXPA02005789A (da)
MY (1) MY125978A (da)
NO (1) NO328682B1 (da)
NZ (1) NZ519378A (da)
PL (1) PL200836B1 (da)
PT (4) PT1242364E (da)
SI (1) SI1352895T1 (da)
SK (1) SK286987B6 (da)
TR (1) TR200401432T4 (da)
TW (1) TWI258462B (da)
WO (1) WO2001044170A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
JP4731468B2 (ja) * 2003-05-12 2011-07-27 ファイザー・プロダクツ・インク Ｐ２ｘ７受容体のベンズアミド阻害剤
US20070032465A1 (en) * 2003-05-29 2007-02-08 Nigel Boughton-Smith Pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha
EP1644041A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
WO2004105796A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
AU2005258911A1 (en) * 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H`1,2,4!triazin-2-YL!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
JP2008504363A (ja) * 2004-06-29 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｐ２ｘ７受容体のベンズアミド阻害剤を利用する併用療法
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
US20060063834A1 (en) * 2004-09-09 2006-03-23 Frangioni John V Substituted adamantanes, and methods of making the same
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
EP1906960A4 (en) * 2005-07-11 2010-03-10 Astrazeneca Ab NEW COMBINATION 1
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
TW200819416A (en) * 2006-09-05 2008-05-01 Astrazeneca Ab Novel process 470
JP4934223B2 (ja) 2008-02-06 2012-05-16 アストラゼネカ・アクチエボラーグ 化合物
NZ587799A (en) 2008-03-25 2012-06-29 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ES2380908T3 (es) 2009-04-14 2012-05-21 Affectis Pharmaceuticals Ag Antagonistas de p2x7r novedosos y su uso
GB2469915A (en) * 2009-04-30 2010-11-03 Astrazeneca Ab 2-chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec- 1-ylmethyl)-benzamide hydrochloride salt
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
EP2322149A1 (en) 2009-11-03 2011-05-18 Universidad del Pais Vasco Methods and compositions for the treatment of ischemia
EP2569281A1 (en) 2010-05-14 2013-03-20 Affectis Pharmaceuticals AG Novel methods for the preparation of p2x7r antagonists
JP2013249256A (ja) * 2010-09-15 2013-12-12 Astellas Pharma Inc 脂肪性肝疾患治療薬
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
TW201309706A (zh) 2011-07-22 2013-03-01 Actelion Pharmaceuticals Ltd 作為ｐ２ｘ７受體拮抗劑之雜環醯胺衍生物
AU2013210682B2 (en) 2012-01-20 2017-05-25 Idorsia Pharmaceuticals Ltd Heterocyclic amide derivatives as P2X7 receptor antagonists
WO2014091415A1 (en) 2012-12-12 2014-06-19 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
EP2935211B1 (en) 2012-12-18 2016-11-09 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as p2x7 receptor antagonists
EP2956457B1 (en) 2013-01-22 2016-11-23 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
CA2896790C (en) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
WO2023158601A2 (en) * 2022-02-15 2023-08-24 The Children's Medical Center Corporation Compositions and methods relating to atp/p2x7r signaling inhibition
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3029241A (en) 1962-04-10 Phenylpbperazinylacyl anilines
US3464998A (en) 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US3732305A (en) 1970-03-03 1973-05-08 Us Army S-substituted thiosulfuric acid derivatives and preparation thereof
US3789072A (en) 1970-04-22 1974-01-29 Squibb & Sons Inc Carboxamides
FR2346011A1 (fr) 1976-02-02 1977-10-28 Orsymonde Acetanilido-piperazines
ZA825719B (en) 1981-09-03 1983-06-29 Recordati Chem Pharm Alkanoylanilides
CA2015473C (en) 1989-04-28 1998-04-14 Iwao Kinoshita Triphenylmethane derivatives
US6021024A (en) * 1992-02-21 2000-02-01 Kabushiki Kaisha Toshiba Magnetic disk drive having a constant skew angle
CA2091194A1 (en) 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
ES2125285T3 (es) 1992-07-31 1999-03-01 Bristol Myers Squibb Co Derivados inhibidores de la reabsorcion de adenosina de difenil-oxazoles, tiazoles e imidazoles.
ATE197146T1 (de) 1993-08-10 2000-11-15 Black James Foundation Gastrin-und cck-rezeptorligande
US5530018A (en) * 1994-02-04 1996-06-25 G. D. Searle & Co. Meso-azanoradamantanes
GB9409150D0 (en) 1994-05-09 1994-06-29 Black James Foundation Cck and gastrin receptor ligands
DE69530081T2 (de) 1994-05-27 2003-12-24 Black James Foundation Gastrin- und cck-antagonisten
AU701127B2 (en) 1994-10-27 1999-01-21 Merck & Co., Inc. Muscarine antagonists
DE19608653A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU1903799A (en) * 1997-12-05 1999-06-28 Eisai Co. Ltd. Compositions and methods for modulating the activity of fibroblast growth factor
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6018089A (en) * 1997-12-09 2000-01-25 Shell Oil Company Process for separating linear internal olefins from branched internal olefins
WO1999031096A1 (en) 1997-12-18 1999-06-24 Shaman Pharmaceuticals, Inc. Piperazine derivatives useful as hypoglycemic agents
US6271265B1 (en) 1998-05-19 2001-08-07 Centaur Pharmaceuticals, Inc. Amide therapeutics for the treatment of inflammatory bowel disease
KR100710091B1 (ko) 1999-04-09 2007-04-25 아스트라제네카 아베 아다만탄 유도체
SE9901875D0 (sv) 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
US6555451B1 (en) * 2001-09-28 2003-04-29 The United States Of America As Represented By The Secretary Of The Navy Method for making shallow diffusion junctions in semiconductors using elemental doping
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds

Also Published As

Publication number Publication date
DE60036968T2 (de) 2008-08-14
CN1434794A (zh) 2003-08-06
EP1352897A2 (en) 2003-10-15
ES2215777T3 (es) 2004-10-16
DE60032823T2 (de) 2007-11-08
CY1107838T1 (el) 2013-06-19
IS6406A (is) 2002-05-31
EE05134B1 (et) 2009-02-16
EP1352896A3 (en) 2003-12-03
ATE261933T1 (de) 2004-04-15
BR0016395A (pt) 2002-08-27
NO20022856L (no) 2002-08-16
HK1046678B (zh) 2004-12-03
DK1352895T3 (da) 2007-06-11
SI1352895T1 (sl) 2007-08-31
SK8412002A3 (en) 2003-02-04
HUP0300616A3 (en) 2004-08-30
TR200401432T4 (tr) 2004-08-23
EE200200330A (et) 2003-10-15
EP1352895A3 (en) 2003-12-03
CY1106357T1 (el) 2011-10-12
KR20020061646A (ko) 2002-07-24
DE60034155D1 (de) 2007-05-10
ATE358117T1 (de) 2007-04-15
MXPA02005789A (es) 2002-09-18
ATE376994T1 (de) 2007-11-15
ATE350364T1 (de) 2007-01-15
WO2001044170A1 (en) 2001-06-21
PL355913A1 (en) 2004-05-31
PT1352897E (pt) 2007-03-30
SK286987B6 (sk) 2009-08-06
DE60009147T2 (de) 2005-04-21
AR035325A1 (es) 2004-05-12
TWI258462B (en) 2006-07-21
HK1046678A1 (en) 2003-01-24
AU2244401A (en) 2001-06-25
US20070082957A1 (en) 2007-04-12
CZ20022093A3 (cs) 2003-01-15
EP1352897A3 (en) 2003-12-03
US7132457B2 (en) 2006-11-07
BRPI0016395B8 (pt) 2021-05-25
PT1242364E (pt) 2004-07-30
JP2005320340A (ja) 2005-11-17
PL200836B1 (pl) 2009-02-27
NO20022856D0 (no) 2002-06-14
CO5251381A1 (es) 2003-02-28
BR0016395B1 (pt) 2013-10-08
AU780506B2 (en) 2005-03-24
IS2246B (is) 2007-06-15
HK1057035A1 (en) 2004-03-12
US7297818B2 (en) 2007-11-20
KR20070012883A (ko) 2007-01-29
CA2393352C (en) 2011-08-30
AU2005202321A1 (en) 2005-06-23
US20080139636A1 (en) 2008-06-12
EP1242364B1 (en) 2004-03-17
JP3710418B2 (ja) 2005-10-26
CY1106602T1 (el) 2012-01-25
EP1352895A2 (en) 2003-10-15
US20090176853A1 (en) 2009-07-09
ES2279031T3 (es) 2007-08-16
DE60034155T2 (de) 2007-12-13
MY125978A (en) 2006-09-29
EP1352895B1 (en) 2007-03-28
DE60032823D1 (de) 2007-02-15
EP1352896B1 (en) 2007-10-31
CA2393352A1 (en) 2001-06-21
DE60036968D1 (de) 2007-12-13
AU2005202321B2 (en) 2008-05-22
IL189758A0 (en) 2008-06-05
PT1352896E (pt) 2007-12-19
JP2003517035A (ja) 2003-05-20
US6881754B2 (en) 2005-04-19
IL150124A0 (en) 2002-12-01
KR100710110B1 (ko) 2007-04-20
EP1352897B1 (en) 2007-01-03
HUP0300616A2 (hu) 2003-07-28
DK1242364T3 (da) 2004-06-21
EP1352896A2 (en) 2003-10-15
EP1862451A1 (en) 2007-12-05
DE60009147D1 (de) 2004-04-22
US20030013704A1 (en) 2003-01-16
PT1352895E (pt) 2007-05-31
US20050049303A1 (en) 2005-03-03
NZ519378A (en) 2004-02-27
EP1242364A1 (en) 2002-09-25
DK1352897T3 (da) 2007-04-10
ES2294219T3 (es) 2008-04-01
CN1312120C (zh) 2007-04-25
ES2282546T3 (es) 2007-10-16
NO328682B1 (no) 2010-04-26

Similar Documents

Publication Publication Date Title
DK1352896T3 (da) Adamantanderivater til behandling af inflammations-, immun- og hjertekarsygdomme
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1143977T3 (da) 2-oxy-benzoxazinonderivater til behandling af obesitas
DK1028954T3 (da) Substituerede imidazoler egnede til behandling af inflammatoriske sygdomme
NO20014379D0 (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
DK1459749T3 (da) (S,S)-reboxetin til behandling af inkontinens
NO20051503D0 (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
DK1165576T3 (da) Fremgangsmåde til fremstilling af amin-platin-komplekser
IS7202A (is) Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum
NO20015542D0 (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
DK1150991T3 (da) Præparater til behandling af inflammatoriske reaktioner
DK199800837A (da) Anlæg til behandling af emner
NO20015772L (no) Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
DK0983275T3 (da) Nye triptolidderivater, der er nyttige til behandling af autoimmune sygdomme
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
DK1200114T3 (da) PPAR delta inhibitorer til behandling af kardiovaskulære sygdomme
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
NO20022253L (no) Middel til behandling av hepatitt C
IS2153B (is) S-nítrósóþíól til meðferðar við blóðrásartruflunum
DK1459748T3 (da) (S,S)-reboxetin til behandling af perifer neuropati
DK1226125T3 (da) Fremgangsmåde til fremstilling af mavesårsmidler